Cann Group (ASX:CAN) shared significant developments at its Annual General Meeting on November 6, 2024. The company, focused on cannabis medicine innovation, detailed strategic steps toward positive cash flow and profitability. Key initiatives include cost management, revenue optimization, and business expansion.
Cann Group Limited has made considerable progress in the past year by implementing a strategic program aimed at achieving profitability and growth. The company has successfully managed operational costs and is now working towards reaching an EBITDA breakeven point. This objective is supported by a recent rights issue to raise $6.25 million. Looking forward, the company plans to expand its business through two major projects initiated last year. With a focus on innovation and leadership in the cannabis sector, Cann Group is poised for a promising future.
The company has undergone significant changes over the past 12 months, focusing on operational adjustments and growth. We initiated a strategic program with three critical steps aimed at establishing a successful and profitable business. The first step was to refine operational costs to ensure financial manageability and sustainability. This was completed by mid-2024, effectively reshaping the company's costs to meet these objectives. The second step involves reaching an EBITDA breakeven point, with a focus on reviewing revenue streams for maximum efficiency and profitability. The third step will focus on expanding the profitable business. Over the past year, Cann Group initiated two major projects to drive growth and strengthen its position in the medicinal cannabis industry. I express confidence in a positive and prosperous future for Cann Group, with a commitment to innovation and leadership in the cannabis sector.